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Background: The diagnostic golden standard for gout is to detect monosodium urate (MSU) crystals in synovial
fluid. While some gout classification criteria include this variable, most gout diagnoses are based on clinical features.
This discrepancy between clinical practice and classification criteria can hinder gout epidemiological studies. Here,
the objective was to validate gout diagnoses (International Classification of Diseases (ICD)-10 gout codes) in primary
and secondary care relative to five classification criteria (Rome, New York, ARA, Mexico, and Netherlands). The
frequency with which MSU crystal identification was used to establish gout diagnosis was also determined.
Methods: In total, 394 patients with ≥1 ICD-10 gout diagnosis between 2009 and 2013 were identified from the
medical records of two primary care centers (n = 262) and one secondary care center (n = 132) in Gothenburg,
Sweden. Medical records were assessed for all classification criteria.
Results: Primary care patients met criteria cutoffs more frequently when ≥2 gout diagnoses were made. Even then,
few primary care patients met the Rome and New York cutoffs (19 % and 8 %, respectively). The ARA, Mexico, and
Netherlands cutoffs were met more frequently by primary care patients with ≥2 gout diagnoses (54 %, 81 %, and
80 %, respectively). Mexico and Netherlands cutoffs were met more frequently by the rheumatology department
patients (80 % and 71 %, respectively), even when patients with only 1 gout diagnosis were included. Analysis of
MSU crystals served to establish gout diagnoses in only 27 % of rheumatology department and 2 % of primary care
cases.
Conclusions: If a patient was deemed to have gout at ≥2 primary care center or ≥1 rheumatology-center visits
according to an ICD-10 gout code, the positive predictive value of this variable in relation with the Mexico and
Netherlands classification criteria was ≥80 % for both primary care and rheumatology care settings in Sweden. MSU
crystal identification was rarely used to establish gout diagnosis.
Keywords: Gout, Classification criteria, Validity of diagnosisBackground
Gout is characterized by increased levels of uric acid in
the blood, which lead to the accumulation of monoso-
dium urate crystals (MSU) in the joints and tissue. This
induces a strong inflammatory reaction that causes great
pain. Gout may affect any joint, but it most commonly
affects the lower extremities and has a nocturnal onset.
The inflammation generally subsides within 2 weeks.
Gout is the most common inflammatory arthritic dis-
ease; its worldwide prevalence is 1–2 % [1–4], although* Correspondence: mats.dehlin@vgregion.se
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cultural factors.
Since 1961, the golden standard for diagnosing gout
has been the detection of intracellular (IC) MSU crystals
by polarized light microscopy of the synovial fluid (SF)
from the affected joint [5, 6]. However, studies have indi-
cated that this method is rarely used for diagnosis in
clinical practice [7, 8].
Gout has been diagnosed in the past by using several
classification criteria (Table 1). These were developed on
the basis of expert opinion to facilitate epidemiological
studies and improve comparability between studies. The
earliest were the 1963 Rome [9] and 1966 New York
(NY) [10] criteria, which relied largely on the presenceticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Overview of the criteria and cutoffs used in historical algorithms to diagnose gout
Criteria Rome 1963 New York 1966 ARA 1977 Mexico 2010 Netherlands 2010
Cutoff for gout classification ≥2 of 4 criteria ≥2 of 4 criteria 6 of 12 criteria OR
presence of MSU
in SF




Serum uric acid, μmol/L, Male >420 female >360 >2 SD normal >2 SD normal >350 (3.5 points)
Presence of tophi X X X X X (13 points)
MSU crystals in SF or tissue x (x)
History of attacks of painful joint swelling with
abrupt onset and resolution within 2 weeks
≥2 attacks ≥2 attacks
A history or observation of podagra X X
Rapid response to colchicine treatment,
defined as a major reduction in the objective
signs of inflammation within 48 h
X
More than one attack of acute arthritis X X
Maximum inflammation developed within 1
day
X X X (0.5 point)
Oligoarthritis attack X
Redness observed over the joints X X X (1 point)
First MTP joint painful or swollen X
Unilateral first MTP joint attack X
Unilateral tarsal joint attack X X
Asymmetrical swelling within a joint on X-ray X
Subcortical cysts without erosions on X-ray X
Joint culture negative for organisms during
attack
X
Mono and/or oligoarticular attacks X X (2 points)
Male sex X (2 points)
MTP1 involvement X (2.5 points)
Hypertension or more than one cardiovascular
diseaseb
X (1.5 points)
aA summed score of 4 or less excludes gout; 8 or more suggests gout; between 4 and 8 suggests the need for SF analysis
bCardiovascular disease was defined as angina pectoris, myocardial infarction, heart failure, cerebrovascular accident, transient ischemic attack or peripheral
vascular disease
Abbreviations: MSU monosodium urate, MTP metatarsophalangeal, SF synovial fluid
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(Table 1). Subsequent criteria, namely, the 1977 ARA
[11] and the 2010 Mexico [12] criteria, incorporated
several clinical characteristics of gout that are often
used in clinical practice, such as monoarthritis with
rapid onset and pronounced signs of inflammation. The
Netherlands criteria were published in 2010, emphasiz-
ing clinical parameters and not primarily considering
synovial fluid analysis [13]. Despite all the existing cri-
teria, there is still a need for new classification criteria,
which are currently being developed by ACR/EULAR
(11). These new criteria are likely to be based on the ele-
ments used by previous classification systems because
several of these features were found to highly and accur-
ately discriminate between patients with and without
gout in a Delphi exercise conducted in 2013 involvingboth patients and physicians [14]. The new algorithm is
also likely to include criteria based on new imaging
techniques [15].
Several studies conducted over the past two decades
have shown that the prevalence of gout is rising [16–18].
This highlights the importance of large-scale epidemio-
logical studies that aim to identify the risk factors for de-
veloping gout and for poor gout outcomes, such as
coronary vascular disease and death. Epidemiological
studies that assess the health and economic consequences
of gout are also warranted. Such studies could be based
on medical record databases. However, before the Inter-
national Classification of Diseases (ICD) codes for gout
can serve as data sources for epidemiological studies, the
validity of these codes must be determined. Several studies
show that the validity of ICD codes for gout ranges from
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fair, in UK databases [21, 22].
Sweden has a number of health care registers that
serve as unique national sources of data for large epi-
demiological studies. In particular, the Swedish National
Patient Register (NPR), which was established in 1964,
contains complete national inpatient medical records
since 1987. Furthermore, a recent study showed that by
2011, 99 % of all annual somatic and psychiatric hospital
discharges were registered in the inpatient part of the
NPR [23]. In 2001, an outpatient register for secondary
care was added to the NPR. By 2011, 87 % of annual sec-
ondary care outpatient visits were recorded in the NPR
[24]. Both registers have been used extensively for epi-
demiological research. The ICD codes for several dis-
eases have a high diagnostic validity, with positive
predictive values (PPV) ranging between 85 and 95 %
[23]. For example, the PPVs for the diagnosis of myocar-
dial infarction and rheumatoid arthritis were 98 [25] and
95 % [26], respectively. However, the validity of ICD
codes for diagnosing gout has not yet been assessed.
The primary objective of the present study was to
evaluate the validity of ICD-10 codes for gout diagnosis
in Sweden, as indicated by calculating the PPVs relative
to the five classification criteria. The secondary objective
was to determine the frequency with which the presence
of IC MSU crystals in the SF was used to diagnose gout.
Methods
Setting
The study population consisted of all patients who were
diagnosed with gout between 2009 and 2013 in two pri-
mary care centers and one specialized rheumatology de-
partment with in- and outpatient care in Gothenburg.
Gothenburg is a city in western Sweden with approxi-
mately 533,000 inhabitants as of 2013. In Sweden, all in-
habitants have a personal identification number that is
used to register their health care visits in the NPR. The
NPR for Gothenburg also includes primary care visits.
The medical data that are collected in the NPR include
primary and secondary diagnoses. However, the present
study only considered the primary diagnoses. Since
1997, all diagnoses have been registered according to the
Swedish version of the ICD-10.
The present study included the records of two primary
care clinics (Olskroken and Masthugget) because the
majority of patients with gout are usually diagnosed and
treated by physicians in primary care centers. The two
primary care clinics were chosen from the 30 primary
care centers in Gothenburg. They both represent mid-
size primary care clinics in average income areas, with
approximately 17,000 (Olskroken) and 8000 (Masthugget)
enlisted patients, respectively. Moreover, because more se-
vere cases may be referred to specialized rheumatologyclinics, the records from the only clinic in the area that
provides specialized rheumatology care were also
reviewed. This clinic is the largest rheumatology unit
in the area with approximately 7500 patients enlisted
and 15,000 appointments per year. Ethical approval for
the study was received from the Ethical Review Board
of Gothenburg, Sweden. Informed consent from the
patients was not needed since the data were studied in
a group level and were anonymized.
Selection of cases and review of clinical records
Between 2009 and 2013 in Olskroken and Masthugget,
173 and 89 patients in total were diagnosed with gout at
least once, respectively. During the same period, 132 pa-
tients were diagnosed with gout in the specialized
rheumatology department at Sahlgrenska University
Hospital. Only four patients included were present in
both the patient selections from the primary care center
and the rheumatology department.
Two rheumatologists reviewed the electronic medical
records from the primary care centers and one trained
research nurse assistant and two rheumatologists reviewed
the records from the specialized rheumatology depart-
ment. All reviews were performed according to a struc-
tured protocol that assessed all variables in the Rome, NY,
ARA, Mexico, and Netherlands classification criteria,
which are listed in Table 1. Furthermore, information re-
garding age, sex, and comorbidity was extracted. Patients
were considered to have comorbidity if it was mentioned
in the clinical record or they were prescribed medication
for a comorbidity.
The PPV was calculated by dividing the number of pa-
tients who met each set of the classification criteria
(each of which are considered gold standards) by the
number of patients who were diagnosed with gout in the
medical record. Sensitivity and specificity were not cal-
culated because this would have required a second
population to determine the proportions of false and
true negatives.
Statistical analyses
The primary care group (including the patients from
both primary care centers) and the secondary care group
were analyzed separately. Descriptive statistics were used
to summarize the demographic and clinical characteris-
tics of the two groups. When comparing categorical
data, χ2 test or, when appropriate, Fisher’s exact test,
were used. All statistical analyses were performed using
IBM SPSS version 22 and SAS 9.3.
Results
Patient characteristics
In total, 394 patients were diagnosed at least once with
an ICD-10 code indicating gout during the study period
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Of these, 262 were diagnosed at the two primary care
centers, Olskroken and Masthugget; Olskroken had 173
patients (1.0 % of the approximately 17,000 patients en-
listed to this center during the study period) and
Masthugget had 89 patients (1.1% of the approximately
8000 patients enlisted to this center during the study
period).
Of the 262 primary care group patients, 198 (76 %)
were men and 64 (24 %) were women. On average, the
men were younger (median 63.5, range 31–97 years)
than the women (median 66.5, range 43–98 years). The
total primary care group had a median age of 72.5 (range
31–98) years. The majority of the primary care group
patients (n = 155, 59 %) had hypertension. Eighty-eight
patients (34 %) had cardiovascular disease, 61 (23 %) had
diabetes, and 160 (61 %) were being or had been treated
with allopurinol (Table 2).
In total, 132 patients were diagnosed at least once with
an ICD-10 code indicating gout during the study period in
the specialized rheumatology department at Sahlgrenska
University Hospital. Of these, 106 (80 %) were men and
26 (20 %) were women. The men were younger (median
66.5, range 26–91 years) than the women (median 71,
range 34–94 years). The total population had a median
age of 71 (range 26–94) years. The majority (n = 92, 70 %)
had kidney disease and/or hypertension (n = 86, 59 %).
Fifty-four (41 %) had cardiovascular disease, 25 (19 %) had
diabetes, nine (7 %) had undergone organ transplantation
(liver or kidney), 14 (11%) had psoriasis, and 96 (73 %)
were being or had been treated with allopurinol (Table 2).
Validity of ICD-codes of gout
The patients with ≥1, ≥2, or ≥3 ICD-10 gout diagnoses
in the medical records were then assessed for their abil-
ity to meet the cutoffs of each of the five classification
criteria. Table 3 shows the PPVs for the two groups rela-
tive to each criteria set. The PPV patterns of the two
groups were generally similar and increased with num-
ber of visits with a diagnosis of gout, although the pa-
tients in the rheumatology group were generally moreTable 2 Demographic and clinical characteristics of patients in the p




Age, years median (range) 63.5 (31–97)
No. with hypertension (%) 110 (56)
No. with cardiovascular disease (%)a 61 (31)
No. with diabetes (%)a 41 (21)
No. with allopurinol treatment ever (%)a 119 (60)
aComorbidity was considered to be present if it was mentioned in the clinical recorlikely to meet the criteria cutoffs than the primary care
patients. In both groups, patients with a higher number
of visits with a gout diagnosis had higher PPVs of meet-
ing the criteria cutoffs for all criteria evaluated. Com-
pared with those with ≥2 visits, those with only one visit
with a main diagnosis of gout had significantly lower
PPVs (P ≤ 0.03) for all criteria evaluated (see Additional
file 1: Table S1). The frequency of patients in the pri-
mary care group who met the Rome and NY cutoffs was
very low. Only 19 % and 8% of the patients with ≥2 gout
diagnoses met these cutoffs, respectively. The frequency
of primary care patients meeting the ARA cutoff was
higher, especially in cases with ≥2 gout diagnoses (PPV =
54 %). The frequency of patients meeting the Mexico and
Netherlands cutoffs was very high: approximately 80 % of
patients in both groups met the cutoffs for these criteria
when ≥2 gout diagnoses were present.
Clearly, having ≥1 ICD-10 gout diagnosis did not yield
sufficient validity in the primary care setting. For all cri-
teria, the PPVs were less than 50 %. In the rheumatology
group, having ≥1 gout diagnosis yielded high PPVs, ran-
ging from 61 % (NY) to 80 % (Mexico). Likewise, but to
a lesser degree than in the primary care setting, the PPVs
were significantly (P ≤ 0.02) lower in those with only one
visit with a main diagnosis for gout compared to those
with ≥2 gout diagnoses, except for the Netherlands cri-
teria (see Additional file 1: Table S1).
Validity of individual features
As shown in Table 4, SF analysis was rarely used to diag-
nose gout in primary care. Only 6 (2 %) of the 262 pri-
mary care patients underwent this test. The test was
somewhat more common in the rheumatology depart-
ment. Still, only 35 of the 135 patients (27 %) underwent
SF analysis to establish the diagnosis. Similarly, only 6
primary care patients (2 %) and 31 rheumatology pa-
tients (23 %) had a documented presence of tophi. How-
ever, most patients were assessed for serum levels of uric
acid (78 % of primary care patients and 95 % of the
rheumatology patients). The majority of patients tested




n = 64 n = 106 n = 26
66.5 (43–98) 66.5 (26–91) 71 (34–94)
45 (70) 68 (64) 18 (69)
27 (42) 44 (42) 10 (39)
20 (31) 21 (20) 4 (15)
41 (64) 81 (77) 15 (58)
d or medication for the comorbidity was prescribed




Primary care group Rheumatology group
n = 262 n = 84 n = 27 n = 132 n = 83 n = 62
≥1 ICD-10 gout ≥2 ICD-10 gout ≥3 ICD-10 gout ≥1 ICD-10 gout ≥2 ICD-10 gout ≥3 ICD-10 gout
Rome, n 18 16 8 84 61 46
PPV% 7 19 30 64 73 74
95 % c.i. 4- 10 11-27 13 - 47 56 - 72 63 - 83 63 - 85
New York, n 9 7 3 80 57 44
PPV% 3 8 11 61 69 71
95% c.i. 1 - 5 2 - 14 0 - 22 53 - 69 59 - 79 60 - 82
ARA, n 54 45 19 90 65 51
PPV % 21 54 70 68 78 82
95% c.i. 16 - 26 43 - 65 53 - 87 60 - 76 69 - 87 72 - 92
Mexico, n 106 68 24 105 73 54
PPV% 40 81 89 80 88 87
95 % c.i. 34 - 46 73 - 89 77 - 101 73 - 87 81 - 95 79 - 95
Netherlands,n 110 67 24 94 63 43
PPV% 42 80 89 71 76 69
95 % c.i. 36 - 48 71 - 89 77 - 101 63 - 79 67 - 85 57 - 81
Data in the table are the positive predictive values (PPVs) with the corresponding 95% confidence interval (ci)
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patients). Thus, in most cases, the diagnoses were based
on clinical variables. The five most common clinical var-
iables mentioned in the medical records were monoar-
thritis, first metatarsophalangeal (MTP) joint arthritis,
redness over joints, two or more attacks of arthritis, and
unilateral MTP 1 arthritis (Table 5).
Discussion
The present study showed that when an ICD-code for
gout was recorded in at least two patient visits to a pri-
mary care center and at least one patient visit to a
rheumatology department, the diagnosis had relatively
high validity (a PPV of 80 % or more) when compared to
recent classification criteria like the Mexico and
Netherlands criteria. The SF analysis was rarely used toTable 4 Number of patients displaying gout characteristics
Gout characteristics Primary care group (n = 262)
Men
n = 198 (%)
Increaseda serum uric acid 139 (70/89)1,b
Analysis of MSU crystals in SF (%) 6 (3)
Presence of tophi (%) 3 (2)





1Percentage defined as the proportion with abnormally high values out of: 1) all paestablish a diagnosis in primary care. It was also only
used in a minority of secondary care cases to establish
the diagnosis.
Several studies have examined the validity of gout
diagnosis relative to different classification criteria.
When Malik et al. [19] examined the medical records of
289 patients in a Veteran’s Health database, who had at
least two ICD-9 coded episodes of gout, 36 % met the
ARA criteria. However, in the subgroup of 115 patients
who were assessed by a rheumatologist, 83 (73 %) met
the ARA criteria. A similar study by Harrold et al. [20]
was based on a random sample of the 800,000 patients
in four managed care plans. The analysis of the chart re-
views of 200 randomly selected patients who had two
ICD-9 coded episodes of gout revealed that 121 were
rated by physician consensus as having probable/definiteRheumatology group (n = 132)
Women Men Women
n = 64 (%) n = 106 (%) n = 26 (%)
41 (64/87)1,c 82 (77/80)1,d 15 (58/65)1,e
0 34 (32) 1 (4)
3 (5) 27 (23) 4 (15)
tients reviewed and 2) those with an available test results




Primary care group, n = 262 (%) Rheumatology group, n = 132 (%)
Men n = 198 Women n = 64 Men n = 106 Women n = 26
Monoarthritis 238 (60) 130 (66) 36 (56) 59 (56) 13 (50)
First MTP arthritis 220 (56) 115 (58) 29 (45) 64 (60) 12 (46)
Redness over joints 193 (49) 98 (50) 31 (48) 52 (51) 12 (46)
≥2 or more attacks of arthritis 185 (47) 62 (31) 15 (23) 91 (86) 17 (65)
Unilateral first MTP arthritis 178 (45) 98 (50) 24 (38) 46 (43) 10 (39)
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61 %. However, there was low concordance between the
physician assessments and the ARA, Rome, and NY cri-
teria (κ = 0.17, 0.16, and 0.20, respectively).
A key criterion in the Rome and NY algorithms is the
presence of tophi. Moreover, of the four NY algorithm
criteria, one is the presence of MSU crystals in the SF.
This makes these two algorithms difficult to use in the
primary care setting, which is where the vast majority of
gout cases are diagnosed. Indeed, a large prospective epi-
demiological study of gout, the Health Professionals
study, revealed that SF analysis was only performed in
11 % of the participants who had a diagnosis of gout [3,
4]. However, unlike these earlier criteria sets, the Mexico
and Netherlands criteria do not rely on SF analyses. This
probably explains why ICD-10 gout diagnosis in the pri-
mary care setting had good PPVs in our study when
compared to these latter algorithms.
When Roddy et al. (2010) [22] identified primary care
consultations for acute gout in two primary care data-
bases by free-text screening of the medical records, 583
patients were deemed to have consulted for acute gout.
However, the medical records only mentioned features
that were suggestive of acute gout in 312 (55 %) of these
patients. Hence, the quality of the medical records is
crucial. Notably, the differences in our study between
the primary and secondary care medical records re-
garding PPV have also been observed by other studies
[27, 28]. Thus, the PPV of rheumatic diagnoses seems
to be influenced by the medical specialty of the health
care provider.
In the present study, the lack of documentation of the
indications for urate-lowering therapy in the medical re-
cords in primary care presented a problem, particularly
for patients with chronic stable gout without tophi and
infrequent acute joint symptoms. In such cases, espe-
cially if patients lack symptoms and possibly have nor-
mal serum uric acid levels, the administration of
allopurinol may support the diagnosis of gout. This
stresses the need for new classification criteria that ac-
counts for intercritical or chronic gout.
The strengths of the present study include the fact that
the medical records from both primary and secondarycare settings were reviewed. This allowed us to compare
the two settings in terms of gout diagnosis validity. Fur-
thermore, our computerized population-based registers
enabled us to retrieve and review all medical records
from all registered patients with gout within the defined
geographical area and time frame for both the primary
and secondary care providers.
The limitations of the present study include the possi-
bility that not all patients with gout in the given geo-
graphical area during the study period were diagnosed.
It is also possible that some patients with gout were not
cared for by public health care providers. However, since
less than 13 % of the population of Sweden is cared for
in the private health sector [24], the latter patients are
likely to have only a limited effect on the generalizability
of our patient sample. The uncertainty of how represen-
tative our sample is of the general population with gout
is another limitation of this study, one which we are
presently addressing as part of a large epidemiological
study of gout prevalence in western Sweden. Further-
more, there was a lack of relevant information because
of insufficient recording or the lack of performing
relevant tests. However, if this information had been
available, it would have likely increased the rates of
criteria fulfillment. Last but not least, the validity dis-
cussed in this paper is limited because only the PPVs
were calculated. We were unable to calculate the sen-
sitivity, specificity, negative predictive value, likeli-
hood ratio, and reliability of the ICD-10 gout codes.
Further studies on the full validity of the ICD-10 gout
codes are warranted.
Conclusions
In conclusion, this study showed that when patients
were deemed to have gout after ≥2 gout diagnoses in
primary care and ≥1 gout diagnoses in secondary care,
these diagnoses had relatively high validity compared
with the clinically based Mexico and Netherlands classi-
fication criteria. Moreover, the gout diagnoses in both
settings were largely based on clinical parameters; ana-
lyses of MSU crystals in the SF or documentation of
tophi were rarely performed in both primary and sec-
ondary care.
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